NewAmsterdam Pharma Future Growth
Future criteria checks 2/6
NewAmsterdam Pharma is forecast to grow earnings and revenue by 22.9% and 58.4% per annum respectively while EPS is expected to grow by 27% per annum.
Key information
22.9%
Earnings growth rate
27.0%
EPS growth rate
| Biotechs earnings growth | 21.3% |
| Revenue growth rate | 58.4% |
| Future return on equity | n/a |
| Analyst coverage | Good |
| Last updated | 09 Apr 2024 |
Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | 20 | -142 | -74 | -110 | 7 |
| 12/31/2025 | 8 | -139 | -173 | -161 | 7 |
| 12/31/2024 | 11 | -176 | -133 | -159 | 7 |
| 12/31/2023 | 14 | -177 | -141 | -141 | N/A |
| 9/30/2023 | 18 | -166 | -77 | -77 | N/A |
| 6/30/2023 | 15 | -227 | -11 | -11 | N/A |
| 3/31/2023 | 60 | -155 | -1 | -1 | N/A |
| 12/31/2022 | 103 | -23 | 10 | 11 | N/A |
| 9/30/2022 | 97 | -8 | -30 | -29 | N/A |
| 6/30/2022 | 98 | 37 | -64 | -64 | N/A |
| 3/31/2022 | 52 | 4 | -48 | -48 | N/A |
| 12/31/2021 | N/A | -42 | -30 | -30 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: NAMS is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: NAMS is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: NAMS is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: NAMS's revenue (58.4% per year) is forecast to grow faster than the US market (8.1% per year).
High Growth Revenue: NAMS's revenue (58.4% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if NAMS's Return on Equity is forecast to be high in 3 years time